Short-term effects of Dapagliflozin on cardiac biomarkers, fluid retention, renal and pulmonary function in HFrEF patients: not as good as expected
Anno:
2023
Background: Sodium-glucose co-transporter-2 inhibitors (SGLT2-i) are currently a standard therapy for patients with heart failure with reduced ejection fraction (HFrEF). Still, their potential benefits on biomarkers, respiratory function parameters and fluid retention have not been extensively studied. Bioimpedance vector analysis (BIVA) has emerged as a new tool capable of…